An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign … (NCT01218243) | Clinical Trial Compass
CompletedPhase 2
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
China100 participantsStarted 2010-09
Plain-language summary
To evaluate efficacy of BL33 for mild and moderate benign prostatic hyperplasia(BPH).There are trials showing that electroacupuncture on BL33 for mild and moderate BPH is more effective than terazosin. It could reduce the International Prostate Syndrome Score (IPSS) by 6.68±2.84(39.79%),lower urinary symptoms bother of score(BS) and bladder residual urine, and increase maximum urinary flow rate.But the efficacy of BL33 has not been studied. The objective of this study is to evaluate efficacy of BL32 for mild and moderate BPH by comparison with non-acupoint group.
Who can participate
Age range
50 Years – 70 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 50-70 years old
* Mild to moderate BPH evaluated by I-PSS
* Patients having urinary dysfunction more than 3 months
* Patients with stable life signs
* no use of α1 receptor blocker, 5α-reductase inhibitor or traditional Chinese medicine for over 1 week
* Volunteer to join this research and sign the written informed consent prior to receiving treatment
Exclusion Criteria:
* Urinary dysfunction caused by gonorrhea or urinary tract infection
* Oliguria and anuria caused by urinary calculi, prostate cancer, bladder tumor and acute/chronic renal failure
* Urinary dysfunction caused by neurogenic bladder, bladder neck fibrotic and urethral stricture
* Failure of invasive therapy for prostatic obstruction
* Injured local organs, muscle and nerve caused by pelvic operation or historical trauma
* Upper urinary obstruction and hydrocele combined with damaged renal function due to BPH diagnosed by B-ultrasound
* Patients who can't stick to treatment because of economic reason, far distance between home and the hospital or difficult walking etc.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat)
Timeframe: baseline and the 6th week
2
Change of International Prostate Symptom Score(IPSS) at the 6th Week Compared With Baseline(Per-protocol).
Timeframe: baseline and the 6th week
Trial details
NCT IDNCT01218243
SponsorGuang'anmen Hospital of China Academy of Chinese Medical Sciences